Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplant

Table 1 Patient characteristics and univariate survival analysis

Characteristic		Patients (N = 216)	%	Univariate OS p
Year of transplant, median (range)		2007 (2000–2010)		0.03
Age, median (range)		51 (19–71)		0.44
Sex	Male	99	46%	0.42
	Female	117	54%
Conditioning	FM (RIC)	109	50%	0.55
	MA (Cy/TBI or Bu/Cy)	107	50%
Disease	AML	115	53%	0.05
	MDS	32	15%
	NHL	11	5%
	MM	9	4%
	ALL	41	19%
	CML	4	2%
	HL	2	1%
	CLL	1	0%
	MPN	1	0%
Donor type	Related	186	86%	0.47
	Unrelated	30	14%
Match Degree	Complete match	204	94%	0.92
	1 allele or antigen mismatch	10	5%
	2 allele or antigen mismatch	2	1%
Disease status at transplant	Complete remission	126	58%	0.003
	Not in remission	90	42%
CD34+ cells x 10(6)/kg infused, median (range)		6.0 (1.85 - 17.06)		0.74
Monocytes x 10(6)/kg infused, median (range)		250 (25.7 - 1,139)		0.27
Lymphocytes x 10(6) infused, median (range)		419 (3.04 - 1,530)		0.92
Granulocytes x 10(6) infused, median (range)		166 (5.3 - 1,038)		0.4
Days to ANC 500, median (range)		15 (3–101)		0.83
Days to platelet 50,000 median (range)		19 (0–393)		0.67
Maximal grade of acute GVHD	0	99	46%	<0.001
	1	35	16%
	2	49	23%
	3	24	11%
	4	9	4%
Severity of chronic GVHD	None	89	41%	<0.001
	Mild	32	15%
	Moderate	51	24%
	Severe	44	20%
CMV reactivation	Yes	72	33%	0.15
	No	144	67%
Relapse	Yes	47	22%	0.002
	No	169	78%
ALC day +15 > 0.3 x 10(9)/L		97	45%	0.017
AMC day +15 > 0.3 x 10(9)/L		142	66%	0.94
ALC day +30 > 0.3 x 10(9)/L		183	85%	<0.001
AMC day +30 > 0.3 x 10(9)/L		193	89%	0.001
ALC day +60 > 0.3 x 10(9)/L		172	80%	0.0004
AMC day +60 > 0.3 x 10(9)/L		138	64%	<0.001
ALC day +100 > 0.3 x 10(9)/L		158	73%	<0.001
AMC day +100 > 0.3 x 10(9)/L		139	64%	<0.001

ISSN: 2052-1839